The Fecal Incontinence market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2017 to 2030. It evaluates the current treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Fecal Incontinence: An Overview
Fecal incontinence (FI) is the involuntary passage of fecal matter through the anus or inability to control the discharge of bowel contents. The severity of FI can range from unintentional elimination of flatus to the seepage of liquid fecal matter to complete evacuation of the bowel contents.
FI is a challenging condition of diverse etiology and devastating psychosocial impact. Etiologic factors include traumatic, neurologic, congenital, and iatrogenic. Depending on the etiology, FI may have associated symptoms that need to be actively checked with the patient such as urinary incontinence, vaginal bulging, prolapse, rectovaginal fistula, altered bowel habits.
Fecal Incontinence Market Key Facts
According to Delveinsight’s Analysis, in the year 2018, the total prevalent cases of Fecal Incontinence (FI) were 11,259,139 cases and 11,345,694 cases in 2020 in the 7MM.
In 2018, the EU5 countries accounted for 3,630,911 cases of Fecal Incontinence (FI).
Among EU5 countries, Germany has the highest number of prevalent cases of FI, which were 939,249 cases in 2018.
Delveinsight estimates the prevalence of Fecal Incontinence (FI) is more among females as compared to males.
The Fecal Incontinence Market size was found to be USD 1880 million in 2020, which is further expected to increase by 2030. The market is anticipated to increase during the study period owing to the increase in the research and development programs related to FI in recent years.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Fecal Incontinence market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the Fecal Incontinence market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Get the PDF Sample of the Report:- https://www.delveinsight.com/sample-request/fecal-incontinence-market
Fecal Incontinence Epidemiology
The epidemiology section covers insights about the historical and current Fecal Incontinence patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Fecal Incontinence Epidemiology Segmentation
Total Prevalence of Fecal Incontinence
Prevalent Cases of Fecal Incontinence based on Risk Factors
Gender-specific Fecal Incontinence
Prevalence of Fecal Incontinence based on the frequency
Fecal Incontinence Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Fecal Incontinence market or expected to get launched in the market during the study period. The analysis covers Fecal Incontinence market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Fecal Incontinence Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.
Some of the key companies in the Fecal Incontinence Market include:
9 Meters Biopharma
Palette Life Sciences
And many others
Fecal Incontinence Therapies covered in the report include:
Autologous Muscle-Derived Cells – Autologous muscle progenitor cells, which are isolated from skeletal muscle biopsies and expanded ex vivo before injection into the urethral sphincter, are a potential alternative therapy that may benefit patients with FI by augmenting sphincter function.
RDD-0315 – RDD-0315 is a topical gel containing an alpha-agonist that contracts the smooth muscle of the anal sphincter.
Get More Detailed Insights into the Emerging Therapies & Key Companies:- https://www.delveinsight.com/sample-request/fecal-incontinence-market
Table of Content
1. Key Insights
2. Executive Summary
3. Fecal Incontinence Competitive Intelligence Analysis
4. Fecal Incontinence Market Overview at a Glance
5. Fecal Incontinence Disease Background and Overview
6. Fecal Incontinence Patient Journey
7. Fecal Incontinence Epidemiology and Patient Population
8. Fecal Incontinence Treatment Algorithm, Current Treatment, and Medical Practices
9. Fecal Incontinence Unmet Needs
10. Key Endpoints of Fecal Incontinence Treatment
11. Fecal Incontinence Marketed Products
12. Fecal Incontinence Emerging Therapies
13. Fecal Incontinence Seven Major Market Analysis
14. Attribute Analysis
15. Fecal Incontinence Market Outlook (7 major markets)
16. Fecal Incontinence Access and Reimbursement Overview
17. KOL Views on the Fecal Incontinence Market.
18. Fecal Incontinence Market Drivers
19. Fecal Incontinence Market Barriers
21. DelveInsight Capabilities
*The table of contents is not exhaustive; the final content may vary.
Request Sample Report here:- https://www.delveinsight.com/sample-request/fecal-incontinence-market
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States